These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
217 related items for PubMed ID: 9187909
21. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder. Pantazopoulos D, Ioakim-Liossi A, Karakitsos P, Aroni K, Kakoliris S, Kanavaros P, Kyrkou KA. Anticancer Res; 1997; 17(1B):781-6. PubMed ID: 9066620 [Abstract] [Full Text] [Related]
27. Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Krüger S, Müller H. Br J Urol; 1995 Apr; 75(4):480-4. PubMed ID: 7788260 [Abstract] [Full Text] [Related]
28. Expression of p21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value. Lipponen P, Aaltomaa S, Eskelinen M, Ala-Opas M, Kosma VM. Eur Urol; 1998 Sep; 34(3):237-43. PubMed ID: 9732201 [Abstract] [Full Text] [Related]
29. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Rodríguez-Alonso A, Pita-Fernández S, González-Carreró J, Nogueira-March JL. Eur Urol; 2002 Feb; 41(2):182-8; discussion 188-9. PubMed ID: 12074407 [Abstract] [Full Text] [Related]
30. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda MA, Bellot J, Abboh CC, Mazerolles C, Chopin DK. Cancer; 1997 Oct 15; 80(8):1472-81. PubMed ID: 9338472 [Abstract] [Full Text] [Related]
31. Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior? Doganay L, Altaner S, Bilgi S, Kaya E, Ekuklu G, Kutlu K. Int Urol Nephrol; 2003 Oct 15; 35(2):181-8. PubMed ID: 15072490 [Abstract] [Full Text] [Related]
32. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA. Hum Pathol; 1998 Feb 15; 29(2):146-54. PubMed ID: 9490274 [Abstract] [Full Text] [Related]
34. Immunohistochemical analysis of nm23 protein in transitional cell carcinoma of the bladder. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T. Br J Urol; 1995 Dec 15; 76(6):708-13. PubMed ID: 8535713 [Abstract] [Full Text] [Related]
35. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Gao JP, Uchida T, Wang C, Jiang SX, Matsumoto K, Satoh T, Minei S, Soh S, Kameya T, Baba S. Int J Oncol; 2000 Mar 15; 16(3):469-75. PubMed ID: 10675477 [Abstract] [Full Text] [Related]
39. Detection of P53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications. Kuczyk MA, Serth J, Hervatin C, Arndt H, Derendorf L, Thon WF, Jonas U. World J Urol; 1994 Mar 15; 12(6):345-51. PubMed ID: 7881474 [Abstract] [Full Text] [Related]